StockData
Estrella Immunopharma, Inc. logo

Estrella Immunopharma, Inc. (ESLA) stock

ESLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLAW
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.33−0.05 (-12.74%)

Close on Nov 17, 2026Market cap $14.42MP/E –Yield –

Earnings

Estrella Immunopharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Estrella Immunopharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Estrella Immunopharma has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Estrella Immunopharma puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Estrella Immunopharma filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?